These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

929 related items for PubMed ID: 30019801

  • 1. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
    Zhang J, Liu N, Zhang A, Bao X.
    J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.
    Xu X, Deng F, Lv M, Chen X.
    Arch Gynecol Obstet; 2017 Feb; 295(2):451-458. PubMed ID: 27913927
    [Abstract] [Full Text] [Related]

  • 4. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C, Yao K, Li L, Yi T, Zhao X.
    Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
    Solmaz U, Mat E, Dereli ML, Turan V, Peker N, Tosun G, Dogan A, Adiyeke M, Ozdemir A, Gungorduk K, Sanci M, Yildirim Y.
    J BUON; 2015 Jan; 20(3):847-54. PubMed ID: 26214639
    [Abstract] [Full Text] [Related]

  • 10. Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?
    Yoneoka Y, Ishikawa M, Uehara T, Shimizu H, Uno M, Murakami T, Kato T.
    J Gynecol Oncol; 2019 Sep; 30(5):e81. PubMed ID: 31328461
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
    Morimoto A, Nagao S, Kogiku A, Yamamoto K, Miwa M, Wakahashi S, Ichida K, Sudo T, Yamaguchi S, Fujiwara K.
    Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
    Wang DF, Zhang GN, Peng CR, Shi Y, Shi XW.
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jun 25; 56(6):385-392. PubMed ID: 34154313
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.